Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acorda Therapeutics, Inc.
Acorda Therapeutics' Preclinical Pipeline Named One of the 10 Most Promising Neuroscience Projects Available for Partnering by Windhover
September 5th, 2008
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company's preclinical pipeline has been selected by Windhover Information and an independent neuroscience expert as one of the top 10 most interesting neuroscience projects in development available for strategic partnering. Acorda's preclinical pipeline comprises three programs: a monoclonal antibody (rhIgM22), being studied in collaboration with Mayo Clinic for the regeneration of myelin on nerve fibers damaged by multiple sclerosis (MS); a family of proteins called neuregulins being studied in various therapeutic applications for both neurological and cardiac diseases, including MS, stroke and congestive...
Source: Health Business Week (2008-09-05)
|
